Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Long-Term Deferred Tax (2016 - 2020)

Historic Long-Term Deferred Tax for Lineage Cell Therapeutics (LCTX) over the last 5 years, with Q4 2020 value amounting to $62.0 million.

  • Lineage Cell Therapeutics' Long-Term Deferred Tax rose 1014.91% to $62.0 million in Q4 2020 from the same period last year, while for Dec 2020 it was $62.0 million, marking a year-over-year increase of 1014.91%. This contributed to the annual value of $62.0 million for FY2020, which is 1014.91% up from last year.
  • Lineage Cell Therapeutics' Long-Term Deferred Tax amounted to $62.0 million in Q4 2020, which was up 1014.91% from $56.3 million recorded in Q4 2019.
  • In the past 5 years, Lineage Cell Therapeutics' Long-Term Deferred Tax registered a high of $62.0 million during Q4 2020, and its lowest value of $49213.0 during Q4 2016.
  • In the last 5 years, Lineage Cell Therapeutics' Long-Term Deferred Tax had a median value of $40.6 million in 2017 and averaged $39.5 million.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Long-Term Deferred Tax surged by 8248996.61% in 2017, and later tumbled by 523.56% in 2018.
  • Lineage Cell Therapeutics' Long-Term Deferred Tax (Quarter) stood at $49213.0 in 2016, then skyrocketed by 82489.97% to $40.6 million in 2017, then decreased by 5.24% to $38.5 million in 2018, then surged by 46.12% to $56.3 million in 2019, then rose by 10.15% to $62.0 million in 2020.
  • Its last three reported values are $62.0 million in Q4 2020, $56.3 million for Q4 2019, and $38.5 million during Q4 2018.